ArticleCell research2018
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.
Article in Cell research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis.Apoptosis : an international journal on programmed cell death · 2026Article
- A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.Cancer immunology research · 2025Article
- Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39.The Journal of experimental medicine · 2025Article
- Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.Advances in respiratory medicine · 2024Review
- Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.Cancer immunology, immunotherapy : CII · 2024Article
- Immunologic tumor microenvironment modulators for turning cold tumors hot.Cancer communications (London, England) · 2024Review
- Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.Frontiers in immunology · 2024Review
- Review
- Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal transduction and targeted therapy · 2022Review
- A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.International journal of molecular sciences · 2022Review
- Article
- Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.Chemical science · 2021Article
- The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.Pharmaceutics · 2021Review
- Trial watch: intratumoral immunotherapy.Oncoimmunology · 2021Review
- Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.Cancers · 2020Article
- Immunotherapies and Combination Strategies for Immuno-Oncology.International journal of molecular sciences · 2020Review
- Development of bispecific antibodies in China: overview and prospects.Antibody therapeutics · 2020Review
- Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.Frontiers in immunology · 2020Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.